TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
Dr Andrew Goldsborough will be presenting "TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines" at 15:45 on 12th June 2025
The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzymes, or physical stress. This means that current RNA vaccines require deep freezing (-50°C or lower) to remain stable, making global distribution costly and logistically complex.
Join us at the World Vaccine Congress next week as we showcase our latest breakthrough in mRNA-LNP stability, TheraPHIX™! We’re thrilled that our CEO, Andrew Goldsborough will be speaking on 31st October at 10am in Theatre 6. His talk, *"TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines"* will delve into how we’re reshaping the future of vaccine delivery and therapeutic stability.
We are delighted to announce our sponsorship
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com